SPC365

The evaluation of the European SCORE2 in a Portuguese population

Session: Comunicações Orais (Sessão 5) - Risco CV, Prevenção e Reabilitação Cardíaca 1 - Foco nos Scores de Risco
Speaker: Margarida Temtem

Congress: CPC 2022
Topic: J. Preventive Cardiology
Theme: 28. Risk Factors and Prevention
Subtheme: 28.2 Risk Factors and Prevention – Cardiovascular Risk Assessment
Session Type: Comunicações Orais
FP Number: ---
Authors: Margarida Temtem; Roberto Palma Dos Reis; Marco Serrão; Debora sá; Marina Santos; Carolina Soares; Ana Célia Sousa; Sónia Freitas; Eva Henriques; Mariana Rodrigues; Sofia Borges; Ilídio Ornelas; António Drumond; Maria Isabel Mendonça

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><strong><span style="font-size:11.0pt">Background:</span></strong> </span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><span style="font-size:11.0pt"><span style="color:black">In</span></span><span style="font-size:11.0pt"><span style="background-color:white"><span style="color:black"> 2021, the European Society of Cardiology updated the Cardiovascular Disease (</span></span></span></span></span><span style="font-size:12pt"><span style="font-family:Calibri,"><span style="font-size:11.0pt"><span style="background-color:white"><span style="color:black">CVD) risk stratification in asymptomatic individuals with the validation of European SCORE2. </span></span></span><span style="font-size:11.0pt"><span style="color:black">This new score was developed to estimate 10-year fatal and non-fatal CVD risk in European individuals aged 40&ndash;69 years without previous CVD or diabetes. </span></span><span style="font-size:11.0pt">However, the Portuguese population was not included in SCORE2 project.</span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><strong><span style="font-size:11.0pt">Purpose: </span></strong></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><span style="font-size:11.0pt">Analyse the new European SCORE2 and its influence on MACE prediction in a Portuguese population.</span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><strong><span style="font-size:11.0pt">Methods:</span></strong> </span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><span style="font-size:11.0pt">A cohort of 1,100 individuals (mean age of 53.3&plusmn;6.9 and 74.1% male) was prospectively surveyed during an extended follow-up (<span style="color:black">mean of 4.9&plusmn;3.4 years). Population was stratified into three SCORE2 risk categories (low, moderate and high) and MACE were analysed in each group. Kaplan-Meier estimated the differences in the three survival curves of SCORE2 for MACE occurrence. A multivariate Cox regression analysis with hypertension, smoking, dyslipidemia, kidney failure was performed to calculate the hazard risk of SCORE2 for MACE. </span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><strong><span style="font-size:11.0pt">Results:</span></strong> </span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><span style="font-size:11.0pt">The higher percentage of our population (58.9%) was assigned to the moderate risk. In the higher risk category of SCORE2,&nbsp; 40% presented MACE and 15.3% had no-MACE (p&lt;0.0001). At ten-year follow-up for MACE occurrence, the probability of survival was 98.3%, 89.6% and 78.1 in the low, moderate and high risk categories, respectively (p&lt;0.0001). After multivariate Cox regression, SCORE2 remained in the model with an HR=8.90 (p=0.001) in the highest category. </span><span style="font-size:11.0pt"><span style="background-color:white">SCORE2 compared with the others risk factors, showed a better&nbsp; discrimination capacity for MACE (C-index=0.707) relatively to risk factors only (C-index=0.633), with statistical significance (p=0.001).</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><strong><span style="font-size:11.0pt">Conclusions:</span></strong></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,"><span style="font-size:11.0pt">The new SCORE2 enhanced the identification of individuals at higher risk of developing MACE</span><span style="font-size:11.0pt"> and also performed a good risk dis</span><span style="font-size:11.0pt">crimination for MACE in this portuguese population.</span></span></span></p>